Analysis of induced pluripotent stem cells carrying 22q11.2 deletion

Translational Psychiatry

Volumn 6, Issue 11, 2016, Pages

  Toyoshima, M ^a   Akamatsu, W ^b,c   Okada, Y ^b,d   Ohnishi, T ^a   Balan, S ^a   Hisano, Y ^a   Iwayama, Y ^a   Toyota, T ^a   Matsumoto, T ^b   Itasaka, N ^a   Sugiyama, S ^a   Tanaka, M ^a   Yano, M ^e   Dean, B ^f   Okano, H ^b   Yoshikawa, T ^a  

^a RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c JUNTENDO UNIVERSITY   (Japan)

^d AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^f UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ASCORBIC ACID; BRAIN DERIVED NEUROTROPHIC FACTOR; GLIAL DERIVED NEUROTROPHIC FACTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MICRORNA; MICROTUBULE ASSOCIATED PROTEIN 2; MITOGEN ACTIVATED PROTEIN KINASE P38; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NESTIN; NEUROTROPHIC FACTOR; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; TRANSCRIPTION FACTOR SOX10; UNCLASSIFIED DRUG; DGCR8 PROTEIN, HUMAN; RNA BINDING PROTEIN;

ADULT; ARTICLE; ASTROCYTE; CELL MIGRATION; CHROMOSOME DELETION 22Q11; CHROMOSOME DELETION 22Q11.2; CONTROLLED STUDY; DGCR8 GENE; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; INDUCED PLURIPOTENT STEM CELL; NERVE CELL DIFFERENTIATION; NERVE FIBER GROWTH; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; TRANSCRIPTOMICS; UPREGULATION; WESTERN BLOTTING; ADOLESCENT; BRAIN; CASE CONTROL STUDY; CELL LINE; COPY NUMBER VARIATION; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE DETECTION; MALE; METABOLISM; NERVE CELL; PATHOLOGY; PHENOTYPE; PLURIPOTENT STEM CELL;

22Q11 DELETION SYNDROME; ADOLESCENT; ADULT; BRAIN; CASE-CONTROL STUDIES; CELL LINE; DNA COPY NUMBER VARIATIONS; FEMALE; GENETIC CARRIER SCREENING; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MICRORNAS; NEURONS; PHENOTYPE; PLURIPOTENT STEM CELLS; RNA-BINDING PROTEINS; SCHIZOPHRENIA;

EID: 84994234202     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2016.206     Document Type: Article

References (49)

1. Merikangas AK, Corvin AP, Gallagher L. Copy-number variants in neurodevelopmental disorders: promises and challenges. Trends Genet 2009; 25: 536-544.
2. Hiroi N. Small cracks in the dam: rare genetic variants provide opportunities to delve into mechanisms of neuropsychiatric disorders. Biol Psychiatry 2014; 76: 91-92.
3. Botto LD, May K, Fernhoff PM, Correa A, Coleman K, Rasmussen SA, et al. A population-based study of the 22q11.2 deletion: phenotype, incidence, and contribution to major birth defects in the population. Pediatrics 2003; 112: 101-107.
4. Karayiorgou M, Simon TJ, Gogos JA. 22q11.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia. Nat Rev Neurosci 2010; 11: 402-416.
5. Edelmann L, Pandita RK, Morrow BE. Low-copy repeats mediate the common 3-Mb deletion in patients with velo-cardio-facial syndrome. Am J Hum Genet 1999; 64: 1076-1086.
6. Gothelf D, Presburger G, Zohar AH, Burg M, Nahmani A, Frydman M, et al. Obsessive-compulsive disorder in patients with velocardiofacial (22q11 deletion) syndrome. Am J Med Genet B Neuropsychiatr Genet 2004; 126b: 99-105.
7. Jonas RK, Montojo CA, Bearden CE. The 22q11.2 deletion syndrome as a window into complex neuropsychiatric disorders over the lifespan. Biol Psychiatry 2014; 75: 351-360.
8. Hiroi N, Takahashi T, Hishimoto A, Izumi T, Boku S, Hiramoto T. Copy number variation at 22q11.2: from rare variants to common mechanisms of developmental neuropsychiatric disorders. Mol Psychiatry 2013; 18: 1153-1165.
9. Stark KL, Xu B, Bagchi A, Lai WS, Liu H, Hsu R, et al. Altered brain microRNA biogenesis contributes to phenotypic deficits in a 22q11-deletion mouse model. Nat Genet 2008; 40: 751-760.
10. Ouchi Y, Banno Y, Shimizu Y, Ando S, Hasegawa H, Adachi K, et al. Reduced adult hippocampal neurogenesis and working memory deficits in the Dgcr8-deficient mouse model of 22q11.2 deletion-Associated schizophrenia can be rescued by IGF2. J Neurosci 2013; 33: 9408-9419.
11. Mukai J, Dhilla A, Drew LJ, Stark KL, Cao L, MacDermott AB, et al. Palmitoylationdependent neurodevelopmental deficits in a mouse model of 22q11 microdeletion. Nat Neurosci 2008; 11: 1302-1310.
12. Mukai J, Tamura M, Fenelon K, Rosen AM, Spellman TJ, Kang R, et al. Molecular substrates of altered axonal growth and brain connectivity in a mouse model of schizophrenia. Neuron 2015; 86: 680-695.
13. Hiroi N, Zhu H, Lee M, Funke B, Arai M, Itokawa M, et al. A 200-kb region of human chromosome 22q11.2 confers antipsychotic-responsive behavioral abnormalities in mice. Proc Natl Acad Sci USA 2005; 102: 19132-19137.
14. Rapoport JL, Addington AM, Frangou S, Psych MR. The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry 2005 10: 434-449.
15. Imaizumi Y, Okano H. Modeling human neurological disorders with induced pluripotent stem cells. J Neurochem 2014; 129: 388-399.
16. Brennand KJ, Simone A, Tran N, Gage FH. Modeling psychiatric disorders at the cellular and network levels. Mol Psychiatry 2012; 17: 1239-1253.
17. Okano H, Yamanaka S. iPS cell technologies: significance and applications to CNS regeneration and disease. Mol Brain 2014; 7: 22.
18. Brennand KJ, Simone A, Jou J, Gelboin-Burkhart C, Tran N, Sangar S, et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011; 473: 221-225.
19. Hook V, Brennand KJ, Kim Y, Toneff T, Funkelstein L, Lee KC, et al. Human iPSC neurons display activity-dependent neurotransmitter secretion: aberrant catecholamine levels in schizophrenia neurons. Stem Cell Rep 2014; 3: 531-538.
20. Bundo M, Toyoshima M, Okada Y, Akamatsu W, Ueda J, Nemoto-Miyauchi T, et al. Increased l1 retrotransposition in the neuronal genome in schizophrenia. Neuron 2014; 81: 306-313.
21. Maekawa M, Yamada K, Toyoshima M, Ohnishi T, Iwayama Y, Shimamoto C, et al. Utility of scalp hair follicles as a novel source of biomarker genes for psychiatric illnesses. Biol Psychiatry 2015; 78: 116-125.
22. Imaizumi Y, Okada Y, Akamatsu W, Koike M, Kuzumaki N, Hayakawa H, et al. Mitochondrial dysfunction associated with increased oxidative stress and alphasynuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. Mol Brain 2012; 5: 35.
23. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-872.
24. Matsumoto T, Fujimori K, Andoh-Noda T, Ando T, Kuzumaki N, Toyoshima M, et al. Functional neurons generated from T cell-derived induced pluripotent stem cells for neurological disease modeling. Stem Cell Rep 2016; 6: 422-435.
25. Yamada K, Hattori E, Iwayama Y, Toyota T, Iwata Y, Suzuki K, et al. Populationdependent contribution of the major histocompatibility complex region to schizophrenia susceptibility. Schizophr Res 2015; 168: 444-449.
26. Bittel DC, Yu S, Newkirk H, Kibiryeva N, Holt A 3rd, Butler MG, et al. Refining the 22q11.2 deletion breakpoints in DiGeorge syndrome by aCGH. Cytogenet Genome Res 2009; 124: 113-120.
27. Matsui T, Takano M, Yoshida K, Ono S, Fujisaki C, Matsuzaki Y, et al. Neural stem cells directly differentiated from partially reprogrammed fibroblasts rapidly acquire gliogenic competency. Stem Cells 2012; 30: 1109-1119.
28. Brennand K, Savas JN, Kim Y, Tran N, Simone A, Hashimoto-Torii K, et al. Phenotypic differences in hiPSC NPCs derived from patients with schizophrenia. Mol Psychiatry 2015; 20: 361-368.
29. Yoon KJ, Nguyen HN, Ursini G, Zhang F, Kim NS, Wen Z, et al. Modeling a genetic risk for schizophrenia in iPSCs and mice reveals neural stem cell deficits associated with adherens junctions and polarity. Cell Stem Cell 2014; 15: 79-91.
30. Yu DX, Di Giorgio FP, Yao J, Marchetto MC, Brennand K, Wright R, et al. Modeling hippocampal neurogenesis using human pluripotent stem cells. Stem Cell Rep 2014; 2: 295-310.
31. Wen Z, Nguyen HN, Guo Z, Lalli MA, Wang X, Su Y, et al. Synaptic dysregulation in a human iPS cell model of mental disorders. Nature 2014; 515: 414-418.
32. Kawahara H, Imai T, Okano H. MicroRNAs in neural stem cells and neurogenesis. Front Neurosci 2012; 6: 30.
33. Im HI, Kenny PJ. MicroRNAs in neuronal function and dysfunction. Trends Neurosci 2012; 35: 325-334.
34. Concepcion CP, Bonetti C, Ventura A. The microRNA-17-92 family of microRNA clusters in development and disease. Cancer J 2012; 18: 262-267.
35. Mogilyansky E, Rigoutsos I. The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ 2013; 20: 1603-1614.
36. Moreau MP, Bruse SE, David-Rus R, Buyske S, Brzustowicz LM. Altered microRNA expression profiles in postmortem brain samples from individuals with schizophrenia and bipolar disorder. Biol Psychiatry 2011; 69: 188-193.
37. Naka-Kaneda H, Nakamura S, Igarashi M, Aoi H, Kanki H, Tsuyama J, et al. The miR-17/106-p38 axis is a key regulator of the neurogenic-To-gliogenic transition in developing neural stem/progenitor cells. Proc Natl Acad Sci USA 2014; 111: 1604-1609.
38. Correa SA, Eales KL. The role of p38 MAPK and its substrates in neuronal plasticity and neurodegenerative disease. J Signal Transduct 2012; 2012: 649079.
39. Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, et al. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 1995; 364: 229-233.
40. Kempf H, Lecina M, Ting S, Zweigerdt R, Oh S. Distinct regulation of mitogenactivated protein kinase activities is coupled with enhanced cardiac differentiation of human embryonic stem cells. Stem Cell Res 2011; 7: 198-209.
41. Ripke S, O'Dushlaine C, Chambert K, Moran JL, Kahler AK, Akterin S, et al. Genomewide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet 2013; 45: 1150-1159.
42. Fenelon K, Mukai J, Xu B, Hsu PK, Drew LJ, Karayiorgou M, et al. Deficiency of Dgcr8, a gene disrupted by the 22q11.2 microdeletion, results in altered shortterm plasticity in the prefrontal cortex. Proc Natl Acad Sci USA 2011; 108: 4447-4452.
43. Toritsuka M, Kimoto S, Muraki K, Landek-Salgado MA, Yoshida A, Yamamoto N, et al. Deficits in microRNA-mediated Cxcr4/Cxcl12 signaling in neurodevelopmental deficits in a 22q11 deletion syndrome mouse model. Proc Natl Acad Sci USA 2013; 110: 17552-17557.
44. Petri R, Malmevik J, Fasching L, Akerblom M, Jakobsson J. miRNAs in brain development. Exp Cell Res 2014; 321: 84-89.
45. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, et al. A microRNA polycistron as a potential human oncogene. Nature 2005; 435: 828-833.
46. Bian S, Hong J, Li Q, Schebelle L, Pollock A, Knauss JL, et al. MicroRNA cluster miR-17-92 regulates neural stem cell expansion and transition to intermediate progenitors in the developing mouse neocortex. Cell Rep 2013; 3: 1398-1406.
47. Li X, Newbern JM, Wu Y, Morgan-Smith M, Zhong J, Charron J, et al. MEK is a key regulator of gliogenesis in the developing brain. Neuron 2012; 75: 1035-1050.
48. Andoh-Noda T, Akamatsu W, Miyake K, Matsumoto T, Yamaguchi R, Sanosaka T, et al. Differentiation of multipotent neural stem cells derived from Rett syndrome patients is biased toward the astrocytic lineage. Mol Brain 2015; 8: 31.
49. Leza JC, Bueno B, Bioque M, Arango C, Parellada M, Do K, et al. Inflammation in schizophrenia: a question of balance. Neurosci Biobehav Rev 2015; 55: 612-626.